Chardan has initiated coverage of 4D Molecular Therapeutics (FDMT) with a Buy rating and 12 month price target of $30, on the potential of its directed evolution AAV platform to tackle historic obstacles to in vivo gene delivery. #ChardanResearch #Biotech

.@OrchestraBioMed (OBIO) is a biomedical company with a business model designed to accelerate high-impact technologies to patients through risk-reward sharing partnerships.

Join us this morning at 11:00 AM ET for a leadership call with @OrchestraBioMed Founder, Chairman, & CEO, David Hochman. For more information, please email corpaccess@ https://t.co/Q1bQrZrbQO #Chardan

Chardan is recruiting for our 2024 Banking Summer #Internship Program! We are accepting applications from students graduating in winter 2024 or spring 2025. Deadline to apply is 8/1/2023. Visit https://t.co/wWJ2TbwxjP for more info & email resumes to careers@chardan.com to apply.

.@OrchestraBioMed (OBIO) is a biomedical company with a business model designed to accelerate high-impact technologies to patients through risk-reward sharing partnerships.

Join us this Thursday, June 29th for a leadership call with @OrchestraBioMed Founder, Chairman, & CEO, David Hochman. For more information, please email corpaccess@ https://t.co/Q1bQrZrbQO #Chardan

To register for the conference and learn more about the confirmed presenting companies, please contact CorpAccess@ https://t.co/XEr4fPQbOF. #ChardanGMConf #CGMC20223 #GeneticMedicines

Chardan’s 7th Annual Genetic Medicines Conference is October 2-3, 2023 in-person, in New York City. This year's event will include two full days of programming featuring fireside chats, presentations, panels and perspectives from groundbreaking thought leaders. #ChardanGMConf

Chardan’s Viral News in Genetic Medicines is a weekly piece that details key news and industry research in the #GeneticMedicines space. To learn more about Viral News in Genetic Medicines and Chardan research, please email info@chardan.com #genetherapy #geneediting #celltherapy

Zura Bio Limited (@NASDAQ: ZURA) is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. Access the report here: https://t.co/v1igIZHAPx or by reaching out to your Chardan sales contact.

Chardan is initiating coverage on Zura Bio with a Buy rating and PT of $14 based on the potential of the company's pipeline of novel, in-licensed antibodies for addressing autoimmune indications. #ChardanResearch #Biotech

Chardan’s Viral News in Genetic Medicines is a weekly piece that details key news and industry research in the #GeneticMedicines space. To learn more about Viral News in Genetic Medicines and Chardan research, please email info@chardan.com #genetherapy #geneediting #celltherapy

Chardan’s Viral News in Genetic Medicines is a weekly piece that details key news and industry research in the #GeneticMedicines space. To learn more about Viral News in Genetic Medicines and Chardan research, please email info@chardan.com #genetherapy #geneediting #celltherapy

We look forward to their contributions to our team! To learn more about Chardan’s career opportunities, please visit https://t.co/wWJ2TbwxjP.

Welcome Chardan’s 2023 Summer Intern class! Over the next 10 weeks, interns will gain an experience that truly mirrors a full-time role through small team environments with excellent exposure to senior leadership and frequent collaboration and connection with colleagues.

ANEW MEDICAL, INC. is an early-stage biotechnology company focused on developing disruptive new therapies to treat neurodegenerative diseases. To learn more about Chardan’s Investment Banking practice and recent transactions, visit https://t.co/C1q5GkhBDj. #ChardanTransactions

Chardan is pleased to act as M&A and capital markets advisor to ANEW MEDICAL, INC. on the announced definitive merger agreement with Redwoods Acquisition Corp. (NASDAQ: RWOD). Read more about the transaction here: https://t.co/eFc3DA33qR.

Chardan’s Viral News in Genetic Medicines is a weekly piece that details key news and industry research in the #GeneticMedicines space. To learn more about Viral News in Genetic Medicines and Chardan research, please email info@chardan.com #genetherapy #geneediting #celltherapy

Chardan is pleased to act as Financial Advisor for @Presto_ai's $10 million PIPE. Presto (@Nasdaq: PRST) provides enterprise-grade AI solutions to some of the nation’s largest hospitality brands. Read more about the transaction here: https://t.co/TyZhojdrz0 #ChardanTransactions

Congratulations to Geulah Livshits, PhD, Senior Research Analyst for ranking in @TipRanks' top 10 health care sector analysts of the past decade! https://t.co/f41oz7Qq5V